AORT
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Artivion, Inc.
- Nom
- Artivion, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $1.1B
- Employés
- 1,800
- PDG
- James Patrick Mackin
- Site web
- https://artivion.com
- Marché
- ADUSARDTBKDCOGTINSPITGR
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 11480 titres (~286656 USD)
- Insiders
- GREEN ANDREW M
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,595,676
Avg sell (VWAP, 90d window) $28.28 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-10
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | GREEN ANDREW M | Sell · S | 11,480 | $24.97 | $286,656 | Form 4 |
| 2026-09-03 | GREEN ANDREW M | Sell · S | 1,493 | $26.02 | $38,842 | Form 4 |
| 2026-09-02 | GREEN ANDREW M | Sell · S | 6,510 | $27.27 | $177,495 | Form 4 |
| 2026-08-19 | Mackin James P | Sell · S | 70,000 | $28.95 | $2,026,850 | Form 4 |
| 2026-08-14 | Berry Lance A | Sell · S | 715 | $28.55 | $20,413 | Form 4 |
| 2026-08-14 | GREEN ANDREW M | Sell · S | 616 | $28.55 | $17,586 | Form 4 |
| 2026-08-12 | Holloway Jean F | Sell · S | 977 | $28.49 | $27,835 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-16 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-07-15 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-07-16 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-14 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-06-13 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-06 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
AORT shows encouraging operational progress with its first profitable year, but the combination of a weak event-driven catalyst (small congressional trades offset by significant insider selling) and stretched…
The first sentence of the analysis written for AORT on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 2.99 · operating margin 6.1%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 61.3% | 64.0% | 64.7% | 64.5% | 66.1% | |
| Ebit Margin | 9.4% | 6.9% | 1.0% | 1.0% | 0.7% | |
| Ebitda Margin | 14.5% | 13.1% | 7.6% | 8.2% | 8.7% | |
| Operating Profit Margin | 6.1% | 10.0% | 1.6% | 2.0% | 2.7% | |
| Pretax Profit Margin | 3.3% | -1.9% | -6.1% | -4.8% | -5.0% | |
| Continuous Operations Profit Margin | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | |
| Net Profit Margin | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | |
| Bottom Line Profit Margin | 2.2% | -3.4% | -8.6% | -6.1% | -4.9% | |
| Current Ratio | 2.989 | 4.341 | 4.851 | 4.979 | 5.510 | |
| Quick Ratio | 2.079 | 3.147 | 3.434 | 3.480 | 3.798 | |
| Solvency Ratio | 0.074 | 0.021 | -0.015 | 0.007 | 0.019 | |
| Cash Ratio | 0.639 | 0.800 | 1.019 | 0.792 | 1.224 | |
| Price To Earnings Ratio | 207.318 | -89.344 | -23.840 | -25.250 | -53.553 | |
| Price To Earnings Growth Ratio | -1.229 | 1.558 | -0.424 | -0.960 | 3.927 | |
| Forward Price To Earnings Growth Ratio | -1.229 | 1.558 | -0.424 | -0.960 | 3.927 | |
| Price To Earnings Diluted Ratio | 217.190 | -89.344 | -23.840 | -25.250 | -53.553 | |
| Price To Earnings Diluted Growth Ratio | -1.311 | 1.558 | -0.424 | -0.960 | 3.927 | |
| Price To Book Ratio | 4.613 | 4.314 | 2.585 | 1.706 | 2.638 | |
| Price To Sales Ratio | 4.685 | 3.067 | 2.058 | 1.546 | 2.655 | |
| Price To Free Cash Flow Ratio | -2,269.736 | 107.849 | 63.930 | -30.576 | -50.606 | |
| Price To Operating Cash Flow Ratio | 54.228 | 53.585 | 38.698 | -94.156 | -306.887 | |
| Debt To Assets Ratio | 0.330 | 0.459 | 0.452 | 0.468 | 0.457 | |
| Debt To Equity Ratio | 0.652 | 1.312 | 1.272 | 1.255 | 1.204 | |
| Debt To Capital Ratio | 0.395 | 0.567 | 0.560 | 0.557 | 0.546 | |
| Long Term Debt To Capital Ratio | 0.358 | 0.532 | 0.520 | 0.519 | 0.506 | |
| Financial Leverage Ratio | 1.974 | 2.857 | 2.812 | 2.683 | 2.637 | |
| Working Capital Turnover Ratio | 2.076 | 1.742 | 1.684 | 1.567 | 1.586 | |
| Operating Cash Flow Ratio | 0.375 | 0.333 | 0.325 | -0.104 | -0.058 | |
| Operating Cash Flow Sales Ratio | 0.086 | 0.057 | 0.053 | -0.016 | -0.009 | |
| Free Cash Flow Operating Cash Flow Ratio | -0.024 | 0.497 | 0.605 | 3.079 | 6.064 | |
| Debt Service Coverage Ratio | 1.840 | 1.309 | 0.661 | 1.083 | 1.406 | |
| Interest Coverage Ratio | 1.006 | 1.134 | 0.227 | 0.340 | 0.481 | |
| Short Term Operating Cash Flow Coverage Ratio | 7.094 | 114.031 | 12.974 | -3.205 | -1.586 | |
| Operating Cash Flow Coverage Ratio | 0.131 | 0.061 | 0.053 | -0.014 | -0.007 | |
| Capital Expenditure Coverage Ratio | 0.977 | 1.987 | 2.534 | -0.481 | -0.197 | |
| Dividend Paid And Capex Coverage Ratio | 0.977 | 1.987 | 2.534 | -0.481 | -0.197 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 35.958 | 29.436 | 38.370 | 31.254 | 42.261 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 61.3% | ▼-2.8% | ▼-2.9% |
| Ebit Margin | 9.4% | ▲2.5% | ▲5.6% |
| Ebitda Margin | 14.5% | ▲1.3% | ▲4.0% |
| Operating Profit Margin | 6.1% | ▼-4.0% | ▲1.6% |
| Pretax Profit Margin | 3.4% | ▲5.3% | ▲6.2% |
| Continuous Operations Profit Margin | 2.2% | ▲5.7% | ▲6.4% |
| Net Profit Margin | 2.2% | ▲5.7% | ▲6.4% |
| Bottom Line Profit Margin | 2.2% | ▲5.7% | ▲6.4% |
| Current Ratio | 2.989 | ▼-1.352 | ▼-1.545 |
| Quick Ratio | 2.079 | ▼-1.068 | ▼-1.109 |
| Solvency Ratio | 0.074 | ▲0.053 | ▲0.053 |
| Cash Ratio | 0.639 | ▼-0.161 | ▼-0.256 |
| Price To Earnings Ratio | 207.318 | ▲296.662 | ▲204.252 |
| Price To Earnings Growth Ratio | -1.229 | ▼-2.787 | ▼-1.803 |
| Forward Price To Earnings Growth Ratio | -1.229 | ▼-2.787 | ▼-1.803 |
| Price To Earnings Diluted Ratio | 217.190 | ▲306.534 | ▲212.150 |
| Price To Earnings Diluted Growth Ratio | -1.311 | ▼-2.870 | ▼-1.869 |
| Price To Book Ratio | 4.613 | ▲0.299 | ▲1.442 |
| Price To Sales Ratio | 4.685 | ▲1.619 | ▲1.883 |
| Price To Free Cash Flow Ratio | -2269.736 | ▼-2377.585 | ▼-1833.908 |
| Price To Operating Cash Flow Ratio | 54.228 | ▲0.643 | ▲105.135 |
| Debt To Assets Ratio | 0.330 | ▼-0.129 | ▼-0.103 |
| Debt To Equity Ratio | 0.651 | ▼-0.660 | ▼-0.487 |
| Debt To Capital Ratio | 0.395 | ▼-0.173 | ▼-0.130 |
| Long Term Debt To Capital Ratio | 0.358 | ▼-0.174 | ▼-0.129 |
| Financial Leverage Ratio | 1.974 | ▼-0.883 | ▼-0.619 |
| Working Capital Turnover Ratio | 2.076 | ▲0.334 | ▲0.345 |
| Operating Cash Flow Ratio | 0.376 | ▲0.043 | ▲0.201 |
| Operating Cash Flow Sales Ratio | 0.086 | ▲0.029 | ▲0.052 |
| Free Cash Flow Operating Cash Flow Ratio | -0.024 | ▼-0.521 | ▼-2.068 |
| Debt Service Coverage Ratio | 1.840 | ▲0.531 | ▲0.581 |
| Interest Coverage Ratio | 1.006 | ▼-0.128 | ▲0.368 |
| Short Term Operating Cash Flow Coverage Ratio | 7.094 | ▼-106.937 | ▼-18.768 |
| Operating Cash Flow Coverage Ratio | 0.131 | ▲0.069 | ▲0.086 |
| Capital Expenditure Coverage Ratio | 0.977 | ▼-1.011 | ▲0.013 |
| Dividend Paid And Capex Coverage Ratio | 0.977 | ▼-1.011 | ▲0.013 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 35.958 | ▲6.522 | ▲0.503 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.07B | $1.19B | $728.5M | $485.2M | $793.3M | |
| Enterprise value | $2.29B | $1.50B | $1.03B | $802.7M | $1.10B | |
| EV / Sales | 5.20x | 3.86x | 2.90x | 2.56x | 3.68x | |
| EV / Op. cash flow | 60.19x | 67.47x | 54.60x | -155.77x | -425.66x | |
| EV / Free cash flow | -2519.06x | 135.80x | 90.20x | -50.58x | -70.19x | |
| EV / EBITDA | 35.96x | 29.44x | 38.37x | 31.25x | 42.26x | |
| Net debt / EBITDA | 3.56x | 6.06x | 11.18x | 12.36x | 11.79x | |
| Current ratio | 2.99x | 4.34x | 4.85x | 4.98x | 5.51x | |
| Income quality | 3.90x | -1.66x | -0.61x | 0.27x | 0.17x | |
| Graham number | $7 | — | — | — | — | |
| Graham net-net | -$5 | -$9 | -$9 | -$9 | -$9 | |
| Tax burden | 66.1% | 177.8% | 142.2% | 128.1% | 100.0% | |
| Interest burden | 35.7% | -28.1% | -581.4% | -462.5% | -719.8% | |
| Working capital | $202.0M | $223.3M | $222.8M | $197.7M | $202.7M | |
| Invested capital | $712.3M | $696.7M | $724.6M | $704.5M | $737.5M | |
| Return on assets | 1.1% | -1.7% | -3.9% | -2.5% | -1.9% | |
| Operating ROA | 3.2% | 4.9% | 0.7% | 0.8% | 1.0% | |
| Return on tangible assets | 2.1% | -3.4% | -8.2% | -5.7% | -4.3% | |
| Return on equity | 2.2% | -4.8% | -10.9% | -6.7% | -4.9% | |
| Return on invested capital | 2.2% | 5.3% | 0.8% | 0.9% | 1.1% | |
| Return on capital employed | 3.4% | 5.4% | 0.8% | 0.9% | 1.1% | |
| Earnings yield | 0.5% | -1.1% | -4.2% | -4.0% | -1.9% | |
| Free cash flow yield | -0.0% | 0.9% | 1.6% | -3.3% | -2.0% | |
| Capex / Op. cash flow | 102.4% | 50.3% | 39.5% | -207.9% | -506.4% | |
| Capex / Depreciation | 173.8% | 46.2% | 32.2% | 47.7% | 54.6% | |
| Capex / Sales | 8.8% | 2.9% | 2.1% | 3.4% | 4.4% | |
| SG&A / Sales | 48.2% | 49.5% | 59.0% | 50.2% | 56.8% | |
| R&D / Sales | 7.0% | 7.3% | 8.1% | 12.4% | 11.9% | |
| Stock comp / Sales | 5.5% | 3.7% | 4.1% | 3.9% | 3.6% | |
| Intangibles / Total assets | 46.4% | 50.4% | 52.9% | 55.9% | 56.9% | |
| Days sales outstanding | 86d | 81d | 76d | 81d | 71d | |
| Days payables outstanding | 34d | 47d | 39d | 39d | 37d | |
| Operating cycle | 283d | 289d | 316d | 325d | 348d | |
| Cash conversion cycle | 249d | 242d | 277d | 286d | 311d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-07 Artivion Q2 Earnings Call Highlights Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
- 2026-08-07 Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
- 2026-08-06 Artivion (AORT) Q2 Earnings Meet Estimates Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
- 2026-08-06 Artivion Reports Second Quarter 2026 Financial Results Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
- 2026-07-28 Artivion to Participate in Upcoming Investor Conferences ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion''s management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel.
- 2026-07-23 Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
- 2026-07-19 Fifth Third Bancorp Buys 123,023 Shares of Artivion, Inc. $AORT Fifth Third Bancorp lifted its stake in Artivion, Inc. (NYSE: AORT) by 58,029.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,235 shares of the company''s stock after acquiring an additional 123,023 shares during the period. Fifth Third